Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LLSAT: Long-term Safety of Linerixibat in PBC
NCT04167358Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Jul 2020
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of linerixibat in cholestatic pruritus, sponsored by GSK. Started Jul 2020; status: active, not recruiting.
02
Drugs
linerixibat
03
Conditions
cholestatic pruritus
Beyond the preview
Go deeper on NCT04167358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04167358.